BioCatalyst

KHK4951, Aflibercept Injection — catalyst calendar

2 verified catalyst event(s) referencing KHK4951, Aflibercept Injection, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08-31
in 2mo
ESTIMATED
 READOUT
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Ag
Phase 2 · Neovascular Age-Related Macular Degeneration (nAMD)
 Kyowa Kirin Co., Ltd. KHK4951, Aflibercept Injection ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-08-31
in 2mo
ESTIMATED
 READOUT
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macul
Phase 2 · Diabetic Macular Edema (DME)
 Kyowa Kirin Co., Ltd. KHK4951, Aflibercept Injection ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.